NEWS BRIEF: Legend Biotech’s revenue doubles on big gains for CAR-T treatment
Cancer treatment maker Legend Biotech Corp. (LEGN.US) reported on Friday its revenue more than doubled to $187 million in the second quarter from $73 million a year earlier, while its…
Legend Holdings shows diversification isn’t always a winning formula
The investment holding company warned it will post a large loss for 2023, as losses from some assets may outweigh declining profits at others Key Takeaways: Legend Holdings warned that…
RELATED ARTICLES
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK -
Will Genscript cash out of Legend Biotech in the face of fat profit temptation?
1548.HK LEGN.US
-
Legend Holdings shows diversification isn’t always a winning formula
3396.HK
-
FAST NEWS: Genscript’s new cancer drug sales surge in third quarter
1548.HK LEGN.US
-
BeiGene’s aggressive expansion brings revenue jolt
BGNE.US 6160.HK 688235.SHG
